The chief purpose of the Clinical Core is to establish and maintain an acute hepatitis C virus (HCV) tissue repository. Better understanding of spontaneous recovery of HCV infection is necessary to improve methods to prevent and treat chronic infection. A major limitation is the rare recognition of acute infection in humans. We have overcome this obstacle by following persons at risk for HCV infection monthly. By screening for HCV infection and careful monitoring of acutely infected persons, we have established an acute infection repository that has already been used by immunologists to advance our understanding of acute hepatitis C. In this competing renewal, the clinical activities are focused in a Clinical Core whose aims are to recruit and monitor HCV antibody negative young injection drug users, to clinically characterize acute infection when it occurs, and to establish and maintain an acute infection repository and distribute the resources to NIH funded investigators. By accomplishing these aims, the Clinical Core will make a major contribution to our understanding of hepatitis C recovery and achieve many of the objectives of RFA-AI-04-028.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Medical Br Galveston
United States
Zip Code
Jarret, Abigail; McFarland, Adelle P; Horner, Stacy M et al. (2016) Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling. Nat Med 22:1475-1481
Hong, MeeAe; Schwerk, Johannes; Lim, Chrissie et al. (2016) Interferon lambda 4 expression is suppressed by the host during viral infection. J Exp Med 213:2539-2552
Yi, MinKyung; Hu, Fengyu; Joyce, Michael et al. (2014) Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzee. J Virol 88:3678-94
Li, Kui; Lemon, Stanley M (2013) Innate immune responses in hepatitis C virus infection. Semin Immunopathol 35:53-72
Wilkins, Courtney; Woodward, Jessica; Lau, Daryl T-Y et al. (2013) IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology 57:461-9
Horner, Stacy M; Park, Hae Soo; Gale Jr, Michael (2012) Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix ?0. J Virol 86:3112-20
Welsch, Christoph; Schweizer, Sabine; Shimakami, Tetsuro et al. (2012) Ketoamide resistance and hepatitis C virus fitness in val55 variants of the NS3 serine protease. Antimicrob Agents Chemother 56:1907-15
Zhou, Yan; Callendret, BenoƮt; Xu, Dan et al. (2012) Dominance of the CD4(+) T helper cell response during acute resolving hepatitis A virus infection. J Exp Med 209:1481-92
Grebely, Jason; Prins, Maria; Hellard, Margaret et al. (2012) Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 12:408-14
Shimakami, Tetsuro; Yamane, Daisuke; Jangra, Rohit K et al. (2012) Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc Natl Acad Sci U S A 109:941-6

Showing the most recent 10 out of 156 publications